

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-1  
REGISTRATION STATEMENT**

*UNDER  
THE SECURITIES ACT OF 1933*

---

**SIGILON THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**2834**  
(Primary Standard Industrial  
Classification Code Number)

**47-4005543**  
(I.R.S. Employer  
Identification Number)

**100 Binney Street, Suite 600  
Cambridge, MA 02142  
(617) 336-7540**  
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Rogério Vivaldi Coelho, M.D.**  
**President and Chief Executive Officer**  
**100 Binney Street, Suite 600  
Cambridge, MA 02142  
(617) 336-7540**  
(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**Marc Rubenstein, Esq.**  
**William Michener, Esq.**  
**Ropes & Gray LLP**  
**Prudential Tower**  
**800 Boylston Street**  
**Boston, MA 02199**  
**(617) 951-7000**

**Peter Handrinos, Esq.**  
**Wesley Holmes, Esq.**  
**Latham & Watkins LLP**  
**200 Clarendon Street, 27th Floor**  
**Boston, Massachusetts 02116**  
**(617) 948-6000**

---

**Approximate date of commencement of proposed sale to public:**  
**As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  333- 250070

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

#### CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Proposed maximum aggregate offering price (1)	Amount of registration fee(2)
Common Stock, \$0.001 par value	\$22,540,000.00	\$2,459.12

- (1) Includes shares that may be issued upon exercise by the underwriters of their option to purchase additional shares.
- (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) of the Securities Act of 1933, as amended. The registrant previously registered securities with a proposed maximum aggregate offering price not to exceed \$122,360,000 on a Registration Statement on Form S-1 (File No. 333-250070), which was declared effective by the Securities and Exchange Commission on December 3, 2020. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of \$22,540,000.00 is hereby registered, which includes shares issuable upon the exercise of the underwriters' option to purchase additional shares.

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.**

### **Explanatory Note and Incorporation By Reference**

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”). This Registration Statement relates to the public offering of common stock, par value \$0.001 per share (“Common Stock”), of Sigilon Therapeutics, Inc. (the “Registrant”), contemplated by the Registration Statement on Form S-1, as amended (File No. 333-250070), initially filed by Sigilon Therapeutics, Inc. with the Securities and Exchange Commission (the “Commission”) on November 13, 2020 (as amended, the “Prior Registration Statement”) pursuant to the Securities Act, which was declared effective by the Commission on December 3, 2020. The contents of the Prior Registration Statement, including all amendments and exhibits thereto, are incorporated by reference into this Registration Statement.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate offering price of shares to be offered in the public offering by \$22,540,000.00, which includes additional shares that the underwriters have the option to purchase. The additional shares of Common Stock that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement.

The required opinion and consents are listed in Part II, Item 16 hereto and filed herewith.

PART II

Information Not Required in Prospectus

Item 16. Exhibit List

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
<a href="#">5.1</a>	<a href="#">Opinion of Ropes &amp; Gray LLP</a>
<a href="#">23.1</a>	<a href="#">Consent of PricewaterhouseCoopers LLP</a>
<a href="#">23.2</a>	<a href="#">Consent of Ropes &amp; Gray LLP (included in Exhibit 5.1)</a>
<a href="#">24.1*</a>	<a href="#">Power of Attorney</a>

\* Previously filed on the signature page to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-250070), originally filed with the Securities and Exchange Commission on November 13, 2020 and incorporated by reference herein.

## Signatures

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of Massachusetts, on December 3, 2020.


### SIGILON THERAPEUTICS, INC.

By: /s/ Rogerio Vivaldi Coelho, M.D.  
Rogerio Vivaldi Coelho, M.D.  
President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Rogerio Vivaldi Coelho, M.D.</u> Rogerio Vivaldi Coelho, M.D.	President and Chief Executive Officer (Principal Executive Officer)	December 3, 2020
<u>/s/ Glenn Reicin</u> Glenn Reicin	Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)	December 3, 2020
<u>*</u> Daniel G. Anderson, Ph.D.	Director	December 3, 2020
<u>*</u> Doug Cole, M.D.	Director	December 3, 2020
<u>*</u> John Cox	Director	December 3, 2020
<u>*</u> Stephen Oesterle, M.D.	Director	December 3, 2020
<u>*</u> Kavita Patel, M.D.	Director	December 3, 2020
<u>*</u> Robert Ruffolo, Jr., Ph.D.	Director	December 3, 2020
<u>*</u> Eric Shaff	Director	December 3, 2020

\*By: /s/ Rogerio Vivaldi Coelho, M.D.  
Rogerio Vivaldi Coelho, M.D.  
Attorney-in-Fact



December 3, 2020

Sigilon Therapeutics, Inc.  
100 Binney Street, Suite 600  
Cambridge, MA 02142

Ladies and Gentlemen:

We have acted as counsel to Sigilon Therapeutics, Inc., a Delaware corporation (the "Company"), in connection with the Registration Statement on Form S-1 (the "Registration Statement") filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Rule 462(b) under the Securities Act for the registration of up to \$22,540,000 of the common stock, \$0.001 par value per share, of the Company. The Registration Statement incorporates by reference the contents of the Company's registration statement on Form S-1 (File No. 333-250070) (the "Prior Registration Statement"), which was declared effective by the Commission on December 3, 2020, including the prospectus included therein (the "Prospectus"). The term "Securities" refers to the shares of the common stock registered pursuant to the Registration Statement, up to 151,661,343 shares, representing the Company's total amount of expected authorized but unissued shares of common stock, less the number of shares to be sold by the Company pursuant to the Prior Registration Statement. The Securities are proposed to be sold pursuant to an underwriting agreement (the "Underwriting Agreement") to be entered into among the Company and Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the underwriters named therein.

In connection with this opinion letter, we have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Securities have been duly authorized and, when issued and delivered pursuant to the Underwriting Agreement and against payment of the consideration set forth therein, will be, validly issued, fully paid and non-assessable.

We hereby consent to your filing this opinion as an exhibit to the Registration Statement and to the use of our name under the caption "Legal Matters" in the Prospectus. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,  
/s/ Ropes & Gray LLP

Ropes & Gray LLP

---

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated August 21, 2020, except for the effects of the reverse stock split discussed in Note 17 to the financial statements, as to which the date is November 30, 2020, relating to the financial statements, which appears in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-250070) of Sigilon Therapeutics, Inc. We also consent to the reference to us under the heading "Experts" in Amendment No. 1 to the Registration Statement on Form S-1 (No. 333-250070) incorporated by reference in this Registration Statement.

/s/ PricewaterhouseCoopers LLP  
Boston, Massachusetts  
December 3, 2020

---